Metastatic Colon Cancer and Single Agent Neoadjuvant Immunotherapy: A Single Institution Experience
Document Type
Conference Proceeding
Publication Date
10-30-2024
Abstract
Pembrolizumab was granted accelerated FDA approval for the treatment of patients with metastatic MMR deficient solid tumors and has shown significant benefit in the treatment of metastatic colorectal cancer. Recently, the NICHE-2 trial demonstrated that neoadjuvant nivolumab plus ipilimumab led to a significant response in locally advanced MMR deficient colon cancer. This report is a single institution's experience regarding the treatment of metastatic colon cancer with neoadjuvant immunotherapy. Since 2022, our institution has treated two patients with neoadjuvant pembrolizumab for metastatic colon cancer and achieved complete clinical and pathologic responses with no residual evidence of malignancy.
Recommended Citation
Applegarth J, Hao S, Bove C, Wasvary H. Metastatic colon cancer and single agent neoadjuvant immunotherapy: a single institution experience. Paper presented at: Michigan Society of Colon and Rectal Surgeons, Annual Meeting; 2024 Oct 30; Ann Arbor, MI.
Comments
Michigan Society of Colon and Rectal Surgeons, Annual Meeting, Ann Arbor, Michigan, October 30, 2024